The recent findings from the BEACON clinical trial, wherein doublet and triplet combinations of EGFR/MAPK-targeted drugs achieved modest efficacy in BRAF-mutant metastatic CRC66, and the realisation that mutant-specific KRAS-G12C inhibitors cannot achieve therapeutic benefit alone67, hold promise that analogous combination regimens could be of efficacy in tumours with high epithelial TGFβ (e.g. CRIS-B). The gene discussed is BRAF; the disease is neoplasm.